Robert Olstein’s CVS Holdings & Trades

First Buy
Q1 2014
Duration Held
47 Quarters
Largest Add
Q1 2014
+92,000 Shares
Current Position
69,000 Shares
$5.2 M Value

Robert Olstein's CVS Position Overview

Robert Olstein (via Olstein Capital Management, L.P.) currently holds 69,000 shares of CVS Health Corporation (CVS) worth $5.2 M, representing 0.98% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.

Based on 13F filings since 2013, Robert Olstein has maintained a long-term strategic position in CVS, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2019, adding 50,000 shares. Largest reduction occurred in Q4 2019, reducing 61,800 shares.

Analysis based on 13F filings available since 2013 Q2

Robert Olstein's CVS Health Corporation (CVS) Holding Value Over Time

Track share changes against reported price movement

Quarterly CVS Health Corporation (CVS) Trades by Robert Olstein

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2014 +92,000 New Buy 92,000 $74.86
Q4 2014 -17,000 Reduce 18.48% 75,000 $96.31
Q1 2015 -18,000 Reduce 24.00% 57,000 $103.21
Q3 2015 -12,000 Reduce 21.05% 45,000 $96.49
Q4 2015 +19,000 Add 42.22% 64,000 $97.77
Q2 2016 +27,000 Add 42.19% 91,000 $95.74
Q3 2016 +17,000 Add 18.68% 108,000 $88.99
Q4 2016 +32,000 Add 29.63% 140,000 $78.91
Q1 2017 -18,075 Reduce 12.91% 121,925 $78.50
Q2 2017 +3,000 Add 2.46% 124,925 $80.46
Q3 2017 -5,925 Reduce 4.74% 119,000 $81.32
Q4 2017 +17,500 Add 14.71% 136,500 $72.50
Q1 2018 +48,500 Add 35.53% 185,000 $62.21
Q2 2018 -21,000 Reduce 11.35% 164,000 $64.35
Q3 2018 -36,000 Reduce 21.95% 128,000 $78.72
Q4 2018 -1,000 Reduce 0.78% 127,000 $65.52
Q1 2019 +50,000 Add 39.37% 177,000 $53.93
Q2 2019 +6,000 Add 3.39% 183,000 $54.49
Q3 2019 +3,300 Add 1.80% 186,300 $63.07
Q4 2019 -61,800 Reduce 33.17% 124,500 $74.29
Q1 2020 +19,500 Add 15.66% 144,000 $59.33
Q3 2020 +23,000 Add 15.97% 167,000 $58.40
Q4 2020 +2,000 Add 1.20% 169,000 $68.30
Q1 2021 +11,000 Add 6.51% 180,000 $75.23
Q3 2021 -3,000 Reduce 1.67% 177,000 $84.86
Q4 2021 -51,000 Reduce 28.81% 126,000 $103.16
Q1 2022 -27,000 Reduce 21.43% 99,000 $101.21
Q2 2022 -23,000 Reduce 23.23% 76,000 $92.66
Q4 2022 +2,000 Add 2.63% 78,000 $93.19
Q1 2023 +40,000 Add 51.28% 118,000 $74.31
Q2 2023 +20,000 Add 16.95% 138,000 $69.13
Q3 2023 +17,000 Add 12.32% 155,000 $69.82
Q4 2023 -13,000 Reduce 8.39% 142,000 $78.96
Q1 2024 -13,000 Reduce 9.15% 129,000 $79.76
Q2 2024 +26,000 Add 20.16% 155,000 $59.06
Q3 2024 +10,000 Add 6.45% 165,000 $62.88
Q4 2024 -42,000 Reduce 25.45% 123,000 $44.89
Q1 2025 -13,000 Reduce 10.57% 110,000 $67.75
Q2 2025 -33,000 Reduce 30.00% 77,000 $68.97
Q3 2025 -8,000 Reduce 10.39% 69,000 $75.39

Robert Olstein's CVS Health Corporation Investment FAQs

Robert Olstein first purchased CVS Health Corporation (CVS) in Q1 2014, acquiring 92,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Robert Olstein has held CVS Health Corporation (CVS) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Robert Olstein's largest addition to CVS Health Corporation (CVS) was in Q1 2014, adding 92,000 shares worth $6.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Robert Olstein's firm, Olstein Capital Management, L.P., owns 69,000 shares of CVS Health Corporation (CVS), valued at approximately $5.2 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, CVS Health Corporation (CVS) represents approximately 0.98% of Robert Olstein's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Robert Olstein's peak holding in CVS Health Corporation (CVS) was 186,300 shares, as reported at the end of Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.